Taken together, Alice T. Shaw not only ranks first in publication volume but also has four studies among the ten most cited references, underscoring her significant contributions and leadership in the field of ALK-TKI therapy for NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.